UPB — Upstream Bio Income Statement
0.000.00%
Last trade - 00:00- $516.99m
- $175.48m
- $2.85m
Annual income statement for Upstream Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 1.21 | 2.38 | 2.37 | 2.85 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 25.1 | 42.5 | 80.1 | 163 |
| Operating Profit | -23.9 | -40.1 | -77.8 | -160 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -23.9 | -20.5 | -62.8 | -143 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -23.9 | -20.5 | -62.8 | -143 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -23.9 | -20.5 | -62.8 | -143 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -23.9 | -38.3 | -76.4 | -143 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.465 | -0.745 | -1.49 | -2.66 |